share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5:募資說明書
美股SEC公告 ·  05/17 16:15

Moomoo AI 已提取核心訊息

Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $30,000,000. This update, detailed in a prospectus supplement filed on May 17, 2024, follows the company's public float surpassing $75 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. As of the date of the prospectus supplement, Allarity Therapeutics has already sold 18,756,178 shares for gross proceeds of $22,537,915. The prospectus supplement amends the prior prospectus dated November 29, 2023, and the subsequent supplement dated March 19, 2024. Investors are cautioned that investing in Allarity's common stock involves high risk, and they should review the risk factors detailed in the March 19, 2024, prospectus supplement and other referenced documents.
Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $30,000,000. This update, detailed in a prospectus supplement filed on May 17, 2024, follows the company's public float surpassing $75 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. As of the date of the prospectus supplement, Allarity Therapeutics has already sold 18,756,178 shares for gross proceeds of $22,537,915. The prospectus supplement amends the prior prospectus dated November 29, 2023, and the subsequent supplement dated March 19, 2024. Investors are cautioned that investing in Allarity's common stock involves high risk, and they should review the risk factors detailed in the March 19, 2024, prospectus supplement and other referenced documents.
Allarity Therapeutics Inc.宣佈修訂其與Ascendiant Capital Markets, LLC的銷售協議,將其可能發行和出售的普通股總額增加到3000萬美元。2024年5月17日提交的招股說明書補充文件詳細介紹了這一更新,此前該公司的公開持股量於2024年5月2日超過7,500萬美元,這取消了先前根據S-3表格I.B.6號一般指令規定的銷售限制。截至招股說明書補充文件發佈之日,Allarity Therapeutics已經出售了18,756,178股股票,總收益爲22,537,915美元。招股說明書補充文件修訂了2023年11月29日的先前招股說明書以及隨後於2024年3月19日發佈的補充說明書。提醒投資者,投資Allarity的普通股涉及高風險,他們應查看2024年3月19日、招股說明書補充文件和其他參考文件中詳述的風險因素。
Allarity Therapeutics Inc.宣佈修訂其與Ascendiant Capital Markets, LLC的銷售協議,將其可能發行和出售的普通股總額增加到3000萬美元。2024年5月17日提交的招股說明書補充文件詳細介紹了這一更新,此前該公司的公開持股量於2024年5月2日超過7,500萬美元,這取消了先前根據S-3表格I.B.6號一般指令規定的銷售限制。截至招股說明書補充文件發佈之日,Allarity Therapeutics已經出售了18,756,178股股票,總收益爲22,537,915美元。招股說明書補充文件修訂了2023年11月29日的先前招股說明書以及隨後於2024年3月19日發佈的補充說明書。提醒投資者,投資Allarity的普通股涉及高風險,他們應查看2024年3月19日、招股說明書補充文件和其他參考文件中詳述的風險因素。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息